SUMMARY Serum concentrations of prednisolone were measured by radioimmunoassay after the administration of prednisone (10, 20, or 30 mg) by mouth to five healthy volunteers, five patients with severe chronic active liver disease (CALD), and five patients with CALD in remission induced by prednisone. Only minor differences were found between the groups and bioavailability was linearly related to the dose of prednisone (r = 0 993). After prednisone (10 mg) was given by mouth and by vein to similar groups of volunteers and 11 additional patients with CALD, bioavailability of oral prednisone approximated 100 Y. ofthe intravenous dose and no differences were found in the pharmacokinetics of prednisolone. We conclude that prednisone is effectively absorbed and converted to prednisolone in health and CALD and find no pharmacological evidence that either drug would be superior to the other for treating CALD.
1If dehydrogenase, mainly located in the liver (Bush and Mahesh, 1964) . We recently showed that impaired liver function resulted in on significant defect in the metabolism to prednisolone of prednisone given by vein (Schalm et al., 1977) . However, different methods of administering drugs may alter pharmacokinetics (Gibaldi and Feldman, 1972) and the reduction in systemic availability resulting from hepatic metabolism (Gibaldi et al., 1971; Gram and Overo, 1976) when some compounds are given by mouth is known as the 'first pass' effect. Since prednisone is given by mouth for ' CALD, concentrations of serum prednisolone will depend on intestinal absorption of prednisone and its conversion to prednisolone in the liver and elsewhere, as well as upon the dose ingested.
Since little information regarding the bioavailability and pharmacokinetic behaviour of prednisolone after oral prednisone is available in health or liver disease, we have investigated these parameters after different oral doses of prednisone and have compared the bioavailability of prednisone after identical oral and intravenous doses.
Methods

SUBJECTS
To determine dose responses, five healthy volunteers and 10 patients with CALD were studied (Table 1) . Of these, five were untreated and fulfilled functional and histological criteria for severe CALD (Soloway et al., 1972) , and five patients were asymptomatic, having responded to treatment with prednisone by resolution (Soloway etal., 1972) ofearlier histological or functional indicators of disease activity.
For bioavailability studies, five healthy volunteers and 11 additional patients (Table 2) with CALD also participated. Of these, five had severe, untreated CALD and six had responded to treatment with prednisone. All individuals were admitted to a metabolic unit after medications had been discontinued for 24 hours. None had been taking drugs believed to induce microsomal enzymes. Seven 1131 patients were taking azathioprine 50 mg/day 48 hours before the study. For dose response studies, a 19 gauge needle was placed in an antecubital vein and was kept patent throughout the study by irrigation with saline. After a baseline blood sample, patients received (on randomised days) oral doses of 10 or 30 mg prednisone (two or six 5 mg tablets of Meticorten) with 180 ml water. Volunteers were also studied on a third day, receiving 20 mg prednisone (four tablets, 5 mg each) in 180 ml water. Blood samples were drawn at 0 5, one hour, and then hourly for a total of eight hours. Apart from lying down for 30 minutes before samples were taken, patients were up and about.
water or dissolved in 3'3 ml 50% ethanol and given by vein over a five-minute period during a rapid simultaneous infusion of saline. After prednisone was given by vein, additional blood samples were obtained at 0-1 and 0 3 hours.
Samples of blood were centrifuged, the serum then being separated and kept frozen at -70°C until further analysis. Prednisolone was determined by a specific radioimmunoassay which reliably detected prednisolone at concentrations < 40 ng/ml (coefficient of variation < 8 5%) and is described elsewhere (Schalm et al., 1976) .
Measurements of pharmacokinetic parameters of prednisolone included peak time, peak concentrations and elimination half life (Koch-Weser, 1974 ). This last value was calculated by linear regression from the logarithm of serum concentrations, taking at least four points beyond the peak value. The integrated area under the serum concentration curve (AUC) from zero to infinity was calculated by the numerical integration using the trapezoidal rule on a PDP 8/e (Digital Equipment Company, Maynard, MA). The general formula used was (Shull et al., 1976) :
thus, the amount entering the systemic circulation is equal to the integrated concentration over time (2 C dt).
Bioavailability of oral doses was determined (Raaflaub and Dubach, 1975) as follows: oral prednisone oral prednisolone AUC bioavailability IV prednisolone AUC x 100 and volume of distribution was calculated as follows: Vd = 0d693 A /C (Shull et al., 1976 
Results
DOSE RESPONSE STUDIES
Profiles for serum concentrations of prednisolone in volunteers and patients with CALD (Fig. 1) show peak levels of prednisolone at approximately 200 ng/ml, 300 ng/ml, and 500 ng/ml after oral doses of 10, 20, and 30 mg prednisone respectively. No striking differences occurred between patients and volunteers. Peak heights were also similar ( (Schalm et al., 1977) . The delay in peak prednisolone concentrations in the last group is unlikely to have therapeutic significance and may be produced by slower conversion of prednisone to prednisolone by the liver. By contrast, patients whose chronic active liver disease had entered remission as a result of treatment with prednisone, had a shorter prednisolone half life than other groups. This was noted earlier by us when prednisone was given intravenously (Schalm et al., 1977) and we considered that it could most reasonably be attributed to induction of hepatic microsomal enzymes (Kozower et al., 1974) . Preservation of conversion of prednisone to prednisolone despite severely impaired hepatic function implies either abundant 1f dehydrogenase activity in other tissues or maintenance of hepatic hydroxylase activity despite considerable deterioration in conventional clinical and biochemical criteria of hepatic function. Both mechanisms have been described in other circumstances (Bush, 1969; Remmer, 1970) Health and may contribute.
For practical purposes our results show that prednisone and prednisolone are likely to be equally effective at the same dose for the treatment of chronic active liver disease. Our more recent studies (Uribe etal., 1976a ) support this conclusion by demonstrating considerable interconversion between the two compounds regardless of what is administered. In the context of these various findings, it is probably pertinent that prednisone retails (in Rochester, MN) for considerably less than half the price of equivalent doses of prednisolone.
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